SCHEMBL26523800

SCHEMBL26523800

CCCC(C)c1cc(C(C)=O)no1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 12/20 0.39
RAB9A P51151 8/20 0.39
NPC1 O15118 6/20 0.39
ALDH1A1 P00352 5/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 1/20 0.39
TP53 P04637 2/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 2/20 0.37
MAPT P10636 2/20 0.36
CYP2C19 P33261 1/20 0.36
MAPK1 P28482 1/20 0.35
TSHR P16473 1/20 0.35
POLB P06746 2/20 0.35
SCD5 Q86SK9 1/20 0.35
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26526008 0.81 SMN1; SMN2 (0.36) SMN1; SMN2RAB9ANPC1ALDH1A1CYP1A2
SCHEMBL26527397 0.81 THRB (0.45) SMN1; SMN2RAB9ANPC1ALDH1A1CYP1A2
SCHEMBL26527370 0.79 SMN1; SMN2 (0.43) SMN1; SMN2RAB9ANPC1ALDH1A1CYP1A2
SCHEMBL1090650 0.77 SMN1; SMN2 (0.55) SMN1; SMN2RAB9ANPC1ALDH1A1CYP1A2
SCHEMBL14099430 0.74 POLB (0.39) SMN1; SMN2RAB9ANPC1ALDH1A1CYP1A2
SCHEMBL26527407 0.74 NOTUM (0.39) TSHR
SCHEMBL26527389 0.73 EPHX2 (0.32) SMN1; SMN2
SCHEMBL9173573 0.72 SMN1; SMN2 (0.43) SMN1; SMN2RAB9ANPC1ALDH1A1CYP1A2
SCHEMBL11721070 0.71 SMN1; SMN2 (0.41) SMN1; SMN2RAB9ANPC1ALDH1A1CYP1A2
SCHEMBL26523791 0.70 ALDH1A1 (0.37) SMN1; SMN2RAB9ANPC1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, MUSK, SMN1; SMN2 SMN1; SMN2 3/4885RAB9A 2744/4885NPC1 4135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.